Cargando…

CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics

OBJECTIVE: To examine the differential diagnostic significance of cerebrospinal fluid (CSF) biomarkers reflecting Alzheimer’s disease-related amyloid β (Aβ) production and aggregation, cortical neuronal damage, tau pathology, damage to long myelinated axons and astrocyte activation, which hypothetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeppsson, Anna, Wikkelsö, Carsten, Blennow, Kaj, Zetterberg, Henrik, Constantinescu, Radu, Remes, Anne M, Herukka, Sanna-Kaisa, Rauramaa, Tuomas, Nagga, Katarina, Leinonen, Ville, Tullberg, Mats
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817981/
https://www.ncbi.nlm.nih.gov/pubmed/31167811
http://dx.doi.org/10.1136/jnnp-2019-320826
_version_ 1783463535669411840
author Jeppsson, Anna
Wikkelsö, Carsten
Blennow, Kaj
Zetterberg, Henrik
Constantinescu, Radu
Remes, Anne M
Herukka, Sanna-Kaisa
Rauramaa, Tuomas
Nagga, Katarina
Leinonen, Ville
Tullberg, Mats
author_facet Jeppsson, Anna
Wikkelsö, Carsten
Blennow, Kaj
Zetterberg, Henrik
Constantinescu, Radu
Remes, Anne M
Herukka, Sanna-Kaisa
Rauramaa, Tuomas
Nagga, Katarina
Leinonen, Ville
Tullberg, Mats
author_sort Jeppsson, Anna
collection PubMed
description OBJECTIVE: To examine the differential diagnostic significance of cerebrospinal fluid (CSF) biomarkers reflecting Alzheimer’s disease-related amyloid β (Aβ) production and aggregation, cortical neuronal damage, tau pathology, damage to long myelinated axons and astrocyte activation, which hypothetically separates patients with idiopathic normal pressure hydrocephalus (iNPH) from patients with other neurodegenerative disorders. METHODS: The study included lumbar CSF samples from 82 patients with iNPH, 75 with vascular dementia, 70 with Parkinson’s disease, 34 with multiple system atrophy, 34 with progressive supranuclear palsy, 15 with corticobasal degeneration, 50 with Alzheimer’s disease, 19 with frontotemporal lobar degeneration and 54 healthy individuals (HIs). We analysed soluble amyloid precursor protein alpha (sAPPα) and beta (sAPPβ), Aβ species (Aβ38, Aβ40 and Aβ42), total tau (T-tau), phosphorylated tau, neurofilament light and monocyte chemoattractant protein 1 (MCP-1). RESULTS: Patients with iNPH had lower concentrations of tau and APP-derived proteins in combination with elevated MCP-1 compared with HI and the non-iNPH disorders. T-tau, Aβ40 and MCP-1 together yielded an area under the curve of 0.86, differentiating iNPH from the other disorders. A prediction algorithm consisting of T-tau, Aβ40 and MCP-1 was designed as a diagnostic tool using CSF biomarkers. CONCLUSIONS: The combination of the CSF biomarkers T-tau, Aβ40 and MCP-1 separates iNPH from cognitive and movement disorders with good diagnostic sensitivity and specificity. This may have important implications for diagnosis and clinical research on disease mechanisms for iNPH.
format Online
Article
Text
id pubmed-6817981
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-68179812019-11-12 CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics Jeppsson, Anna Wikkelsö, Carsten Blennow, Kaj Zetterberg, Henrik Constantinescu, Radu Remes, Anne M Herukka, Sanna-Kaisa Rauramaa, Tuomas Nagga, Katarina Leinonen, Ville Tullberg, Mats J Neurol Neurosurg Psychiatry General Neurology OBJECTIVE: To examine the differential diagnostic significance of cerebrospinal fluid (CSF) biomarkers reflecting Alzheimer’s disease-related amyloid β (Aβ) production and aggregation, cortical neuronal damage, tau pathology, damage to long myelinated axons and astrocyte activation, which hypothetically separates patients with idiopathic normal pressure hydrocephalus (iNPH) from patients with other neurodegenerative disorders. METHODS: The study included lumbar CSF samples from 82 patients with iNPH, 75 with vascular dementia, 70 with Parkinson’s disease, 34 with multiple system atrophy, 34 with progressive supranuclear palsy, 15 with corticobasal degeneration, 50 with Alzheimer’s disease, 19 with frontotemporal lobar degeneration and 54 healthy individuals (HIs). We analysed soluble amyloid precursor protein alpha (sAPPα) and beta (sAPPβ), Aβ species (Aβ38, Aβ40 and Aβ42), total tau (T-tau), phosphorylated tau, neurofilament light and monocyte chemoattractant protein 1 (MCP-1). RESULTS: Patients with iNPH had lower concentrations of tau and APP-derived proteins in combination with elevated MCP-1 compared with HI and the non-iNPH disorders. T-tau, Aβ40 and MCP-1 together yielded an area under the curve of 0.86, differentiating iNPH from the other disorders. A prediction algorithm consisting of T-tau, Aβ40 and MCP-1 was designed as a diagnostic tool using CSF biomarkers. CONCLUSIONS: The combination of the CSF biomarkers T-tau, Aβ40 and MCP-1 separates iNPH from cognitive and movement disorders with good diagnostic sensitivity and specificity. This may have important implications for diagnosis and clinical research on disease mechanisms for iNPH. BMJ Publishing Group 2019-10 2019-06-05 /pmc/articles/PMC6817981/ /pubmed/31167811 http://dx.doi.org/10.1136/jnnp-2019-320826 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle General Neurology
Jeppsson, Anna
Wikkelsö, Carsten
Blennow, Kaj
Zetterberg, Henrik
Constantinescu, Radu
Remes, Anne M
Herukka, Sanna-Kaisa
Rauramaa, Tuomas
Nagga, Katarina
Leinonen, Ville
Tullberg, Mats
CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics
title CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics
title_full CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics
title_fullStr CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics
title_full_unstemmed CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics
title_short CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics
title_sort csf biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics
topic General Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817981/
https://www.ncbi.nlm.nih.gov/pubmed/31167811
http://dx.doi.org/10.1136/jnnp-2019-320826
work_keys_str_mv AT jeppssonanna csfbiomarkersdistinguishidiopathicnormalpressurehydrocephalusfromitsmimics
AT wikkelsocarsten csfbiomarkersdistinguishidiopathicnormalpressurehydrocephalusfromitsmimics
AT blennowkaj csfbiomarkersdistinguishidiopathicnormalpressurehydrocephalusfromitsmimics
AT zetterberghenrik csfbiomarkersdistinguishidiopathicnormalpressurehydrocephalusfromitsmimics
AT constantinescuradu csfbiomarkersdistinguishidiopathicnormalpressurehydrocephalusfromitsmimics
AT remesannem csfbiomarkersdistinguishidiopathicnormalpressurehydrocephalusfromitsmimics
AT herukkasannakaisa csfbiomarkersdistinguishidiopathicnormalpressurehydrocephalusfromitsmimics
AT rauramaatuomas csfbiomarkersdistinguishidiopathicnormalpressurehydrocephalusfromitsmimics
AT naggakatarina csfbiomarkersdistinguishidiopathicnormalpressurehydrocephalusfromitsmimics
AT leinonenville csfbiomarkersdistinguishidiopathicnormalpressurehydrocephalusfromitsmimics
AT tullbergmats csfbiomarkersdistinguishidiopathicnormalpressurehydrocephalusfromitsmimics